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Cyclophosphamide (CY) is a cytostatic agent that produces systemic toxicity especially on cells with high proliferative 
capacity, while polysaccharides from Angelica sinensis (AP) have been shown to increase the turnover of gastrointestinal 
mucosal and hemopoietic stem cells.  It is not known whether AP has an effect on CY-induced cytotoxicity on bone 
marrow and gastrointestinal tract.  In this study, we assessed the protective actions of AP on CY-induced leukopenia 
and proliferative arrest in the gastroduodenal mucosa in mice.  Subcutaneous injection of CY (200 mg/kg) provoked 
dramatic decrease in white blood cell (WBC) count and number of blood vessels and proliferating cells in both the 
gastric and duodenal mucosae.  Subcutaneous injection of AP significantly promoted the recovery from leukopenia and 
increased number of blood vessels and proliferating cells in both the gastric and duodenal tissues.  Western blotting 
revealed that CY significantly down-regulated the protein expression of vascular endothelial growth factor (VEGF), c-
Myc and ornithine decarboxylase (ODC) in gastric mucosae but had no effect on epidermal growth factor (EGF) 
expression.   AP also reversed the dampening effect of CY on VEGF expression in the gastric mucosa.  These data 
suggest that AP is a cytoprotective agent which can protect against the cytotoxicity of CY on hematopoietic and 
gastrointestinal tissues when the polysaccharide is co-administered with CY in cancer patients during treatment 
regimen. 
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1. Introduction 
The major side effect of anticancer drugs, e.g. 
cyclophosphamide, is the non-specific cytostatic action on 
normal healthy cells, especially those with high 
proliferating capacity like the hematopoietic and GI tissues 
[1].  The extensive death of the immune cells results in 
leukopenia which severely weakens the immune system of 
cancer patients and therefore greatly increases the chance 
of disseminated infections which could be fetal.   As a 
result, drug-free period is always clinically necessary in 
cancer patients receiving chemotherapy, so as to allow 
their immune systems to restore function [2].  On the other 
hand, the death of GI cells breaks down the physical 
defence of GI system in the host who will become more 
susceptible to antigen originated from GI systems and 
therefore further increases death rate due to opportunistic 
infection [3].  In addition, emesis due to the release of 
serotonin from enterochromaffin cells is also discouraging 
to cancer patients [4].  All of these are the main reasons for 
discontinuation of cancer chemotherapy, which lowers the 
chance of a successful and complete treatment regimen.   
Angelica sinensis, also known as Danggui, has been 
used as a medicinal herb in China for thousands of years 
and renowned for its therapeutic effects on gynecological 
disorders, such as amenorrhea and menopause [5].  Recent 
pharmacological studies demonstrated the polysaccharides 
fraction of Angelica sinensis had radio-protective effects in 
irradiated mice through modulation of proliferative 
response of hemopoietic stem cells [6].  Concerning 
gastrointestinal system, AP was known to be protective 
against ethanol- or indomethacin-induced mucosal damage 
[7].  It was also reported that Angelica sinensis crude extract 
increased the proliferation of gastric epithelial cells 
through modulation of several proliferation-related genes, 
including EGF, ODC, and c-Myc [8-10].  In addition to the 
effect on hemopoietic and gastrointestinal tissues, AP was 
also shown to possess anti-tumor effect [11, 12].  However, 
the protective effect of AP on CY-induced cytotoxicities in 
both the hemopoietic and gastrointestinal tissues was 
undefined.  Any of these actions would extend the 
therapeutic application of CY in cancer patients in which 
the herb could be used together with the cytotoxic agent in 
cancer therapeutic regimen. 
In the present study, we investigated whether AP 
could protect the bone marrow and the gastrointestinal 
tissues from the cytotoxicity of CY in mice.  We also 
profiled the changes of the expression of growth factors in 
gastric tissues in response to the damage by CY and 
protection by AP.  
2. Materials and Methods 
Chemicals and Reagents 
All chemicals and reagents were of analytical grade 
and were purchased from Sigma (Sigma-Aldrich, St. Louis, 
MO, USA) unless otherwise specified.  
Preparation of Angelica sinensis Polysaccharides 
The roots of Angelica sinensis (Oliv.) Diels, Danggui, 
were purchased from Minxian County, Gansu Province, 
China.  Polysaccharides fraction was isolated by the 
ethanol precipitation method as described by Cho et al [7] 
and modified by Ye et al. [10].  Briefly, one hundred grams 
of roots of Angelica were boiled for three four-hour periods 
with water for a total of 12 hours.  After each four-hour 
period of boiling, the water extract was collected and the 
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residue was boiled again with water for another four-hour 
period.  All extracts were finally pooled and mixed with a 
concentrated ethanol solution (final concentration 75% 
v/v) to precipitate the polysaccharide-enriched fraction.  
Two kinds of high performance liquid chromatography 
(HPLC) methods including the high performance anion 
exchange and the gel filtration chromatography, 
respectively [13], were employed to concentrate and 
determine the molecular size of the polysaccharide-rich 
fraction.  The molecular sizes of polysaccharides were 
determined in HPLC (gel filtration column, Biosep SEC-
S3000, Phenomenex, USA; mobile phase 0.15 mol/L NaCl 
solution; detector wavelength 220 nm) combined with the 
phenol-sulfuric acid method [14, 15].  The amounts of 
uronic acids and proteins were also determined [16, 17]. 
The Angelica polysaccharide fraction was found to 
consist of 5 main polysaccharide sub-fractions with the 
following moleculard weights: >670.00, 433.72, 167.55, 
82.10 and 15.54 kD respectively.  The total extracted 
fraction consisted of 97% carbohydrates (about 30% of 
them uronic acids) and 3% proteins.  This polysaccharide-
enriched fraction from Angelica sinensis (AP) was dissolved 
in normal saline (0.9%, w/v, NaCl) before subcutaneous 
injection to animals.    
Experimental animals and drug administration 
This study was conducted with the consent of the 
Committee on the Use of Live Animals in Teaching and 
Research of the University of Hong Kong.  Male ICR mice 
(weighing 25–30 g) were reared on a standard laboratory 
diet (Ralston Purina, Chicago, Illinois, USA) and given tap 
water ad libitum.  Mice were randomly allocated into 5 
treatment groups (n = 8 - 15 in each group) which were 
subject to a 14-day treatment.  Group 1 was the normal 
untreated control (Nor) while groups 2 to 5 received a 
single dose of CY 200 mg/kg daily by subcutaneous 
injection on day 0 and day 7.  In addition, group 2 (NS) 
mice received daily dose of normal saline while groups 3 to 
5 mice received daily dose of AP at 5 (AP5), 10 (AP10) or 25 
(AP25) mg/kg, respectively.  Mice were sacrificed on day 
14 and the gastric and duodenal tissues were collected for 
biochemical and histological assessments.  
Assessment of white blood cell (WBC) count 
Blood samples were collected from the tail arteries on 
day 0, 4, 7, 11 and 14 to monitor the toxicity of CY on bone 
marrow by measuring WBC number in the peripheral 
blood.  Twenty microliters of blood was mixed with 380μl 
of Randolph’s solution. WBC counting was then performed 
by using an improved Neubauer hematocytometer 
(Reichert, U.S.A.).  
Assessment of angiogenesis 
Immunohistochemical staining of microvessels in the 
tissues of stomach and duodenum was performed by using 
von Willebrand factor antibody [18]. The prepared sections 
were incubated with 0.3% H2O2 in methanol and then 
trypsinized in 0.1% trypsin for 30 minutes at room 
temperature followed by washing with 0.01 M phosphate-
buffered saline. The sections were then incubated for 1 
hour with 1.5% normal goat serum, and subsequently 
incubated with polyclonal rabbit anti-human von 
Willebrand factor antibody at dilution of 1:500 in a 
humidified chamber overnight at 4 °C.  Endothelial cells of 
blood vessel were then visualized by applying the DAKO-
staining system (LSAB kit, DAKO, Copenhagen, 
Denmark).  Blood vessels stained with the antibody to von 
Willebrand factor were counted with Leica image 
processing and analysis system at a 200x magnification 
(Q500IW, Leica Imaging Systems, Cambridge, UK). 
Assessment of cell proliferation 
To determine the number of proliferative cells, 
proliferating cell nuclear antigen (PCNA) in gastric and 
duodenal tissues was stained according to the method 
described by Kitajima et al. [19] with some modifications.  
Briefly, re-hydrated sections were immersed in 0.3% H2O2 
solution, followed by immersion in diluted normal serum 
for 1 hour in a humidified container at room temperature.  
They were incubated with anti-PCNA mouse monoclonal 
antibody (PC10, Santa Cruz, USA) in a humidified 
container at 4 °C overnight followed by a 45-minute 
incubation in peroxidase-labeled streptavidin (from DAKO 
kit). Finally the sections were stained with 
diaminobenzidine-H2O2 solution at room temperature.  
The number of stained cells was counted under microscope 
(Q500IW, Leica Imaging Systems, Cambridge, UK) with a 
400x magnification. 
Western blotting 
Protein expressions of VEGF, EGF, ODC and c-Myc in 
gastric tissues were assessed by Western blot analysis.  
Briefly, gastric tissues were homogenized (100 mg/ml) for 
30 seconds in a radioimmune precipitation assay buffer 
(50 mM Tris–HCl, pH 7.5, 150 mM sodium chloride, 0.5% 
α-cholate, 0.1% sodium dodecyl sulphate (SDS), 2 mM 
EDTA, 1% Triton X-100 and 10% glycerol), containing 
1.0 mM phenylmethylsulfonyl fluoride and 1 μg/ml 
aprotinin.  Samples were then centrifuged at 12,000 rpm for 
20 min at 4 °C and the supernatant containing total protein 
was denatured and separated by electrophoresis on a SDS-
polyacrylamide gel (The percentage of the gel was 15% for 
VEGF, 15% for EGF, 10% for ODC and 10% for c-Myc 
protein).  The protein was then transferred to a 
nitrocellulose membrane (Bio Rad, Hercules, CA, USA) 
that was probed with primary antibody against VEGF 
(1:250, Santa Cruz, USA), EGF (1:250, Santa Cruz, USA), 
ODC (1:250, NeoMarkers, USA) or c-Myc (1:250, Santa 
Cruz, USA).  Membranes were developed by using 
enhanced chemiluminescence (ECL) solution and exposed 
on X-ray film. Quantification of bands on the film was 
carried out by video densitometry (Gel Doc 1000, Bio Rad, 
Hercules, USA). 
Statistical Analysis 
Results are expressed as the mean ± standard error 
(S.E.), and statistical comparisons were based on unpaired 
Student’s t test.  A p-value of less than 0.05 was considered 
as statistically significant. 
3. Results 
Effects of Angelica polysaccharides on the recovery from 
cyclophosphamide-induced leukopenia 
Subcutaneous administration of CY resulted in a 
significant drop in WBC number on day 4 and 11 (80% and 
88% respectively) in mice.  Recovery of WBC count started 
on day 4 and day 11 in all treatment groups and returned 
back to the normal level on day 7 and day 14 in NS group.  
AP at all doses did not have any effect on peripheral WBC 
count in CY-treated mice on either day 4 or day 11.  
However, the rate of recovery of WBC number in mice 
treated with AP 5 mg/kg was significantly increased.  In 
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NS group, the time needed for WBC number to recover 
back to normal level was 7 days.  Upon administration of 
AP 5mg/kg once daily, the WBC number could recover in 
5-day period (Fig. 1).  
Figure 1. Effects of Angelica sinensis polysaccharides (AP) 
treatment (given subcutaneously once daily) on white blood cell 
(WBC) number in cyclophosphamide (CY)-treated mice. CY was 
given subcutaneously (200 mg/kg) at day 0 and day 7 and AP 
was also injected subcutaneously once daily during the 14-day 
experimental period. Nor: Normal untreated group; NS: normal 
saline plus CY-treated group; AP5: AP 5 mg/kg plus CY-treated 
group, AP10: AP 10 mg/kg plus CY-treated group, AP25: AP 25 
mg/kg plus CY-treated group, respectively. *P <0.001 compared 
to Nor. †P< 0.05, compared to NS. 
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Figure 2. Effects of Angelica sinensis polysaccharides (AP) 
treatment (given subcutaneously once daily) on the blood vessel 
count in (A) gastric and (B) intestinal mucosae in 
cyclophosphamide (CY given subcutaneously 200 mg/kg)-treated 
mice. Nor: Normal untreated group. NS: normal saline plus CY-
treated group. AP5: AP 5 mg/kg plus CY-treated group, AP10: 
AP 10 mg/kg plus CY-treated group, AP25: AP 25 mg/kg plus 
CY-treated group, respectively.  *P< 0.05, compared to Nor. †P< 
0.05 compared to the NS. 
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Effects of Angelica polysaccharides on angiogenesis in gastric 
and intestinal mucosae 
CY administration significantly decreased the number 
of blood vessels in both the gastric (23%, Fig. 2A) and 
duodenal (25%, Fig. 2B) mucosae.  AP at the doses of 5, 10 
and 25 mg/kg significantly increased the blood vessel 
count per field by 36%, 55% and 64% respectively in gastric 
mucosa.  For duodenal mucosa, only AP 10 and 25 mg/kg 
had significant effects on blood vessel number  (an increase 
of 40% and 57% respectively).  Dose-dependent effect was 
observed in both gastric and duodenal tissues.  
Effects of Angelica polysaccharides on cell proliferation in 
gastric and duodenal mucosae 
Subcutaneous CY administration significantly 
decreased the number of proliferating cell by 48% in gastric 
(Fig. 3A) and by 74% (Fig. 3B) in duodenal mucosae.   
Concerning gastric mucosa, AP 5 mg/kg increased the 
proliferating cell number by 29% while there was a 154% 
and 208% increase in AP10 and AP25 group respectively 
when compared to NS group (Fig. 3A).  Dose dependent 
effect was observed.  Concerning duodenal mucosa, AP at 
the doses of 5 and 10 mg/kg significantly increased the 
proliferating cell count in duodenal mucosa by 131% and 
305% respectively (Fig. 3B).  AP 25 mg/kg however, led to 
an increase of only 93% when compared to the vehicle 
control group (Fig. 3B). 
Effects of Angelica polysaccharides on VEGF, c-Myc, ODC 
and EGF protein expressions in gastric musoca 
As we had demonstrated that both the blood vessel 
and proliferating cell counts in gastric and duodenal 
tissues were significantly affected by CY and AP 
treatments, the expression level of angiogenesis- and 
proliferation-related proteins were studied.  CY 
significantly down-regulated the protein levels of VEGF, c-
Myc and ODC in the gastric mucosa (Fig. 4A, 4B and 4C 
respectively).  There was a 73% decrease in the VEGF 
protein level and a 22% decrease in the c-Myc protein level 
in the corresponding NS group.  A 52% decrease in the 
expression level was noted in the ODC protein expression 
assay.  In contrast, EGF expression was not altered (Fig. 
4D). AP treatment only significantly reversed the 
dampening effect of CY on VEGF expression in a dose-
dependent manner (Fig. 4A).  It was observed that AP 5 
mg/kg resulted in an increase of 75% while both AP 10 and 
25 mg/kg doubled the increase in the VEGF protein 
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expression.  AP treatment did not have any effect on the 
expression of c-Myc, ODC and EGF in the gastric mucosa 
(Fig. 4B, 4C and 4D respectively).  
Figure 3. Effects of Angelica sinensis polysaccharides (AP) 
treatment (given subcutaneously once daily) on the number of 
proliferation cells in (A) gastric and (B) duodenal mucosae in 
cyclophosphamide (CY) given subcutaneously 200 mg/kg-treated 
mice. Nor: Normal untreated group. NS: normal saline plus CY-
treated group. AP5: AP 5 mg/kg plus CY-treated group, AP10: 
AP 10 mg/kg plus CY-treated group, AP25: AP 25 mg/kg plus 
CY-treated group, respectively.  * p<0.05, compared to Nor. 
†P<0.05 compared to NS. 
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Figure 4. Effects of Angelica sinensis polysaccharides (AP) 
treatment (given subcutaneously once daily) on the protein 
expression (in terms of % of change from control) of (A) 
vascular endothelial growth factor (VEGF), (B) c-Myc, (C) 
ornithine decarboxylase (ODC), and (D) epidermal growth factor 
(EGF) in the gastric mucosa in cyclophosphamide (CY given 
subcutaneously 200 mg/kg)-treated mice. Nor: Normal untreated 
group. NS: normal saline plus CY-treated group. AP5: AP 5 
mg/kg plus CY-treated group, AP10: AP 10 mg/kg plus CY-
treated group, AP25: AP 25 mg/kg plus CY-treated group, 
respectively.  * P< 0.05 compared to Nor. †P< 0.05 compared to 
NS. 
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4. Discussion 
In this study, CY produced myelosuppression 
manifested as leukopenia (Fig. 1).  It also significantly 
reduced the blood supply and proliferating cell number in 
both the gastric and duodenal mucosae.  Subcutaneous 
administration of AP at the dose of 5 mg/kg daily 
significantly promoted the recovery rate of immune system 
in mice in a 14-day treatment (Fig. 1).  It also significantly 
increased the number of blood vessel and PCNA-positive 
cell in both the gastric (Fig. 2A and 2B respectively) and 
duodenal tissues (Fig. 3A and 3B respectively).  Dose-
dependent effects were observed in general.  Western blot 
analysis implicated the reduction by CY and normalization 
by AP of blood vessel count was VEGF dependent in 
gastric tissue (Fig. 4A).  On the other hand, the decrease in 
proliferating cell number in gastric mucosa by CY 
administration was found to be c-Myc and ODC-
dependent (Fig 4B and 4C respectively). 
CY is the non-cytostatic drug that acts non-specifically 
on both tumor cells and normal healthy cells with high 
proliferating capacity like immune cells and GI tissues.  It 
exerts its cytotoxic effect via transfer of its alkyl groups to 
DNA, leading to cell cycle arrest and apoptosis.  The major 
site of alkylation within the DNA is the N7 position of 
guanine.  Alkylation of guanine results in depurination by 
excision of guanine residues, causing DNA strand 
breakage through scission of the sugar-phosphate 
backbone [3].  Patients under chemotherapeutic regimen 
are often subject to leukopenia which greatly increases the 
chance of opportunistic infections.  As a result drug-free 
period is routinely introduced during regimen to prevent 
any or even fetal infections.  In this model, we showed that 
7 days were needed for the CY-treated mice to restore their 
immunity to normal level as indicated by WBC count.   
Such a long drug-free period is indeed undesirable because 
it allows the restoration of tumor tissue into active 
proliferating stage [2], as vascular endothelial cells can 
proliferate again and tumor will be nourished by supply of 
nutrients and oxygen.  However, in mice treated with AP 
5mg/kg, it was observed that a 5-day drug free period was 
enough to fully restore their normal immune response (Fig. 
1). The present findings suggest that AP has 
immunostimulatory effect which can accelerate the 
recovery from leukopenia induced by CY and thereby 
shortens the drug-free period to allow a more frequent 
administration of anticancer drug e.g. CY so as to increase 
the efficacy of chemotherapy.  In previous studies, AP has 
been shown to activate polyclonal B cells [20], induce 
interferon [21] and also activate helper T cells [22].  
Lymphocyte proliferation assays, e.g. mitogen-mediated 
lymphocyte proliferation test and mixed lymphocyte 
culture also proved that AP could increase the rate of 
lymphocyte proliferation in vitro [23].  Oral administration 
of You-Gui-Wan, a classical prescription of TCM 
containing AP, was shown to protect mice against 
hydrocoticoid-induced inhibition of IFN-γ, IL-2, IL-4 and 
IL-10 transcription [24].   In addition, vitamin B12, folinic 
acid and biotin identified in AP may also contribute to 
stimulated hematopoiesis [25].   All of these results are 
consistent with the present findings that AP is a tonic to 
hematopoietic system.  
Concerning angiogenesis, it is believed that one of the 
anti-tumor mechanisms of CY is through the suppression 
on endothelial cell growth in tumor bed [26].  In addition, 
the down-regulation of VEGF by CY has been shown to be 
due to p53 activation [27].  This would decrease the blood 
supply to cancer cells so as to reduce nutrients and oxygen 
to support the growth and differentiation of tumor.  
However, it would also adversely affect the repairing 
capacity and the defensive mechanism of the GI mucosae 
that have been damaged during chemotherapy.  In this 
regard, AP was shown to be beneficial to cancer patients 
because it normalized blood vessel number, which could 
probably supply more nutrients and oxygen to gastric and 
duodenal mucosae.  This also promoted the defensive 
mechanism and also the repairing capacity of the GI 
system which has been damaged by CY administration.  
However, it should be noted that AP might also have a 
similar effect on the vascular endothelial cells in tumor 
bed, of which the proliferation and differentiation would 
be enhanced with a good supply of blood flow.  Whether 
or not AP could affect blood vessels in tumors remains 
unknown.  In this regard, further studies are needed to 
clarify this phenomenon. 
CY exerts its cytotoxicity by cross-linking DNA 
strands and activation of p53-dependent growth arrest and 
apoptosis [28].  It was therefore not surprising that CY 
administration resulted in a decrease in the proliferating 
cell number in both the gastric and duodenal tissues.  
Indeed the decrease in cell proliferation in gastric tissue 
was supported by the down-regulation of c-Myc and ODC 
protein in the Western Blot analysis (Fig. 4B and 4C).  It has 
been reported that p53 activation suppresses the 
transcription of c-Myc, an immediate early gene related to 
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cell proliferation in which mitogenic stimulation leads to 
increased expression and drives the cell cycle from G0 to G1 
[27].  Furthermore, c-Myc is known to induce the 
transcriptional activity of ODC gene [29], which is involved 
in polyamine synthesis.  It is likely that the cell cycle-
arresting action of CY in the stomach in this study was due 
to the activation of p53 and therefore leading to the 
suppression of the c-Myc/ODC pathway.  All these 
findings could explain the mechanism of CY on repression 
of  cell proliferation in the gastroduodenal mucosae.  In 
general, dose-dependent effect on the reversal action of AP 
on this suppressive effect could be observed.  Although our 
previous study has shown that ODC was involved in AP-
induced normal gastric epithelial cell proliferation [10], the 
increased proliferating rate in this study was independent 
of the c-Myc, ODC or EGF as indicated by the 
corresponding protein levels in Western Blot analysis.  
However this could be partly contributed to the effect of 
AP on angiogenesis that increased the blood supply to 
tissues for growth and repairment.  
To conclude, the above findings not only provide a 
fundamental insight into the mechanism of CY-induced 
systemic cytotoxicity, particularly in the gastrointestinal 
system, but also propose a role for polysaccharides from 
Angelica sinensis as a cytoprotective agent to spare the 
hemopoietic and gastrointestinal toxicities of CY. Whether 
or not the present study can be translated into practical 
benefits, warrants further investigation. 
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